American International Biotechnology Presented Results from GynecoloGene
Friday, October 9, 2015
American International Biotechnology, LLC recently presented results from GynecoloGene, the world’s first commercially-available next-generation sequencing test for bacterial vaginosis at the XXI FIGO World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada.
Titled "The Microbiome and Women’s Health” and presented by David G. Bostwick, MD, Chief Medical Officer, and William Budd, PhD, Director of Bioinformatics. They discussed GynecoloGene’s advances in application of molecular testing for bacterial vaginosis, enabling complete identification of all bacterial, fungal, and parasitic pathogens and normal commensals, as well as the absolute number and relative proportions of these organisms. The GynecoloGene test requires only a simple vaginal swab, and is run on the Thermo-Fisher Scientific Ion Torrent platform.
"We are excited to be presenting our clinically-important findings at the XXI FIGO World Congress," said Dr. Bostwick. "Bacterial vaginosis afflicts more than ten million American women, and remains a perplexing illness owing to a recurrence rate of more than 50%. Our metagenomics test, validated over the past year in more than 1500 women, provides significant actionable information that assists physicians in managing this disease, and is especially important for those with recurrent vaginosis who have failed therapy. The promise of personalized medicine is now fulfilled.”
Joining Dr. Bostwick and Dr. Budd in the presentation were practicing obstetrician/gynecologists Drs. Daniel McDyer (Jacksonville, FL) and R. Lamar Parker (Winston-Salem, NC).